Are biopsy specimens predictive of HER2 status in gastric cancer patients?

M. Pirrelli, M. L. Caruso, M. Di Maggio, R. Armentano, A. M. Valentini

Research output: Contribution to journalArticle

Abstract

Background: Trastuzumab has been recently proposed as a treatment for patients with HER2-positive advanced/metastatic gastric cancer (GC). Since most patients have inoperable disease at diagnosis, accurate assessment of HER2 status on biopsy specimens is essential to select the patients who may benefit from therapy. Aim: The aim of this study is to establish whether HER2 status assessed on biopsy material could be reliable for treatment decisions using anti-HER2 agents. Methods: The HER2 status was evaluated in 61 consecutive pairs of biopsy and surgical GCs samples by immunohistochemistry and chromogenic in situ hybridization. Results: The overall concordance of HER2 status between biopsy and surgical specimens was 91.8 % with a predictive positive value of 71.4 % and a negative predictive value of 94.4 %. Of five discordant cases, there were three negative and two positive false biopsy results. All the false negative cases showed heterogeneous expression of HER2 protein in surgical samples. Two cases displayed overexpression of the receptors without corresponding gene amplification. Conclusions: HER2 status as evaluated on biopsy samples is a fairly good predictor of HER2 status of surgically-excised GCs. The most important influence for discordant results is tumor heterogeneity. However, HER2 overexpression, especially without coexisting gene amplification, may only be a temporary change in a tumor population. This may explain those cases with positive HER2 evaluation on biopsy material and a negative result on corresponding surgical specimen.

Original languageEnglish
Pages (from-to)397-404
Number of pages8
JournalDigestive Diseases and Sciences
Volume58
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Stomach Neoplasms
Biopsy
Gene Amplification
In Situ Hybridization
Neoplasms
Therapeutics
Immunohistochemistry
Population
Proteins

Keywords

  • CISH
  • Gastric cancer
  • HER2
  • Immunohistochemistry
  • Molecular targeted therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Are biopsy specimens predictive of HER2 status in gastric cancer patients? / Pirrelli, M.; Caruso, M. L.; Di Maggio, M.; Armentano, R.; Valentini, A. M.

In: Digestive Diseases and Sciences, Vol. 58, No. 2, 02.2013, p. 397-404.

Research output: Contribution to journalArticle

@article{693f4bd69a174e7b9d21924af80ffefe,
title = "Are biopsy specimens predictive of HER2 status in gastric cancer patients?",
abstract = "Background: Trastuzumab has been recently proposed as a treatment for patients with HER2-positive advanced/metastatic gastric cancer (GC). Since most patients have inoperable disease at diagnosis, accurate assessment of HER2 status on biopsy specimens is essential to select the patients who may benefit from therapy. Aim: The aim of this study is to establish whether HER2 status assessed on biopsy material could be reliable for treatment decisions using anti-HER2 agents. Methods: The HER2 status was evaluated in 61 consecutive pairs of biopsy and surgical GCs samples by immunohistochemistry and chromogenic in situ hybridization. Results: The overall concordance of HER2 status between biopsy and surgical specimens was 91.8 {\%} with a predictive positive value of 71.4 {\%} and a negative predictive value of 94.4 {\%}. Of five discordant cases, there were three negative and two positive false biopsy results. All the false negative cases showed heterogeneous expression of HER2 protein in surgical samples. Two cases displayed overexpression of the receptors without corresponding gene amplification. Conclusions: HER2 status as evaluated on biopsy samples is a fairly good predictor of HER2 status of surgically-excised GCs. The most important influence for discordant results is tumor heterogeneity. However, HER2 overexpression, especially without coexisting gene amplification, may only be a temporary change in a tumor population. This may explain those cases with positive HER2 evaluation on biopsy material and a negative result on corresponding surgical specimen.",
keywords = "CISH, Gastric cancer, HER2, Immunohistochemistry, Molecular targeted therapy",
author = "M. Pirrelli and Caruso, {M. L.} and {Di Maggio}, M. and R. Armentano and Valentini, {A. M.}",
year = "2013",
month = "2",
doi = "10.1007/s10620-012-2357-3",
language = "English",
volume = "58",
pages = "397--404",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Are biopsy specimens predictive of HER2 status in gastric cancer patients?

AU - Pirrelli, M.

AU - Caruso, M. L.

AU - Di Maggio, M.

AU - Armentano, R.

AU - Valentini, A. M.

PY - 2013/2

Y1 - 2013/2

N2 - Background: Trastuzumab has been recently proposed as a treatment for patients with HER2-positive advanced/metastatic gastric cancer (GC). Since most patients have inoperable disease at diagnosis, accurate assessment of HER2 status on biopsy specimens is essential to select the patients who may benefit from therapy. Aim: The aim of this study is to establish whether HER2 status assessed on biopsy material could be reliable for treatment decisions using anti-HER2 agents. Methods: The HER2 status was evaluated in 61 consecutive pairs of biopsy and surgical GCs samples by immunohistochemistry and chromogenic in situ hybridization. Results: The overall concordance of HER2 status between biopsy and surgical specimens was 91.8 % with a predictive positive value of 71.4 % and a negative predictive value of 94.4 %. Of five discordant cases, there were three negative and two positive false biopsy results. All the false negative cases showed heterogeneous expression of HER2 protein in surgical samples. Two cases displayed overexpression of the receptors without corresponding gene amplification. Conclusions: HER2 status as evaluated on biopsy samples is a fairly good predictor of HER2 status of surgically-excised GCs. The most important influence for discordant results is tumor heterogeneity. However, HER2 overexpression, especially without coexisting gene amplification, may only be a temporary change in a tumor population. This may explain those cases with positive HER2 evaluation on biopsy material and a negative result on corresponding surgical specimen.

AB - Background: Trastuzumab has been recently proposed as a treatment for patients with HER2-positive advanced/metastatic gastric cancer (GC). Since most patients have inoperable disease at diagnosis, accurate assessment of HER2 status on biopsy specimens is essential to select the patients who may benefit from therapy. Aim: The aim of this study is to establish whether HER2 status assessed on biopsy material could be reliable for treatment decisions using anti-HER2 agents. Methods: The HER2 status was evaluated in 61 consecutive pairs of biopsy and surgical GCs samples by immunohistochemistry and chromogenic in situ hybridization. Results: The overall concordance of HER2 status between biopsy and surgical specimens was 91.8 % with a predictive positive value of 71.4 % and a negative predictive value of 94.4 %. Of five discordant cases, there were three negative and two positive false biopsy results. All the false negative cases showed heterogeneous expression of HER2 protein in surgical samples. Two cases displayed overexpression of the receptors without corresponding gene amplification. Conclusions: HER2 status as evaluated on biopsy samples is a fairly good predictor of HER2 status of surgically-excised GCs. The most important influence for discordant results is tumor heterogeneity. However, HER2 overexpression, especially without coexisting gene amplification, may only be a temporary change in a tumor population. This may explain those cases with positive HER2 evaluation on biopsy material and a negative result on corresponding surgical specimen.

KW - CISH

KW - Gastric cancer

KW - HER2

KW - Immunohistochemistry

KW - Molecular targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84876337887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876337887&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2357-3

DO - 10.1007/s10620-012-2357-3

M3 - Article

C2 - 22918687

AN - SCOPUS:84876337887

VL - 58

SP - 397

EP - 404

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 2

ER -